Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Oncolytics Biotech Inc. (OTC: ONCYF).

Full DD Report for ONCYF

You must become a subscriber to view this report.


Recent News from (OTC: ONCYF)

Oncolytics: Significant Pipeline Value In The Fastest Growing Area Of Oncology.
Overview Oncolytics Biotech Inc. is developing an intravenously delivered immuno-oncolytic virus called REOLYSIN (pelareorep). REOLYSIN is a non-pathogenic, proprietary isolate of the unmodified reovirus that: 1) induces selective tumor lysis in various solid tumors and 2) promotes an inflam...
Source: SeekingAlpha
Date: July, 11 2018 10:32
Week In Review: CStone Acquires China Rights To Leukemia Drug In $424 Million Deal
Deals and Financings CStone Pharma of Suzhou acquired rights to a novel cancer drug from Agios (AGIO), a Boston area pharma, in a deal worth up to $424 million (see story ). CStone will have rights to ivosidenib in greater China. It will initially target acute myeloid leukemia ((AML)) and c...
Source: SeekingAlpha
Date: July, 01 2018 07:14

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-240.78630.740.820.74442,324
2018-05-230.71750.790.85130.71958,727
2018-05-220.7880.72950.790.7057379,814
2018-05-210.770.77990.800.77151,572
2018-05-180.760.760.7950.7452386,610

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-05-24177,565442,32440.1437Short
2018-05-23348,986958,72736.4010Short
2018-05-22253,878379,81466.8427Short
2018-05-2157,046151,57237.6362Short
2018-05-18184,712386,61047.7773Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on ONCYF.


About Oncolytics Biotech Inc. (OTC: ONCYF)

Logo for Oncolytics Biotech Inc. (OTC: ONCYF)

lt p gt Oncolytics Biotech is a biotechnology company focused on the development of oncolytic viruses as a potential therapeutic for use in a broad range of cancers. The Company is conducting clinical studies using REOLYSIN , its proprietary formulation of the human reovirus, in some of the most prevalent forms of the disease including lung, colorectal, and pancreatic cancers. Oncolytics clinical program includes a number of human trials at a variety of stages including a Phase III trial in head and neck cancers. The Company has advanced its product manufacturing and intellectual property initiatives in parallel with its clinical development program to support development of a commercial product. lt /p gt

 

Contact Information

 

 

Current Management

  • Matt Coffey / CEO, President
  • Kirk Look / CFO
  • Michael Moore / VP, Investor Relations and Corporate Affairs
  • Wayne Pisano / Chairman
  • Deborah Brown /
  • Matt Coffey /
  • Angela Holtham /
  • John Mark Lievonen /
  • William G. Rice /
  • Bernd R. Seizinger /

Current Share Structure

  • Market Cap: $73,530,705 - 03/15/2018
  • Issue and Outstanding: 119,562,122 - 04/29/2016
  • Float: 116,825,362 - 10/14/2015

 


Recent Filings from (OTC: ONCYF)

Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: May, 15 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: May, 14 2018
Amendment to a previously filed F-10
Filing Type: F-10/AFiling Source: edgar
Filing Date: May, 04 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: April, 25 2018
Registration statement for securities of certain Canadian issuers under the Securities Act of 1933
Filing Type: F-10Filing Source: edgar
Filing Date: April, 25 2018
Appointment of agent for service of process and undertaking
Filing Type: F-XFiling Source: edgar
Filing Date: April, 25 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: April, 20 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: April, 20 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: April, 20 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: April, 06 2018

 

 


Daily Technical Chart for (OTC: ONCYF)

Daily Technical Chart for (OTC: ONCYF)


Stay tuned for daily updates and more on (OTC: ONCYF)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: ONCYF)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ONCYF is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of ONCYF and does not buy, sell, or trade any shares of ONCYF. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/